Division of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University and the Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan.
Am J Pathol. 2011 Sep;179(3):1471-82. doi: 10.1016/j.ajpath.2011.05.019. Epub 2011 Jul 23.
Gestational choriocarcinoma is a malignant trophoblastic tumor. The development of novel molecular-targeted therapies is needed to reduce the toxicity of current multiagent chemotherapy and to treat successfully the chemoresistant cases. The molecular mechanisms underlying choriocarcinoma tumorigenesis remain uncharacterized, however, and appropriate choriocarcinoma animal models have not yet been developed. In this study, we established a choriocarcinoma model by inoculating mice with induced-choriocarcinoma cell-1 (iC³-1) cells, generated from HTR8/SVneo human trophoblastic cells retrovirally transduced with activated H-RAS (HRASV12). The iC³-1 cells exhibited constitutive activation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways and developed into lethal tumors in all inoculated mice. Histopathological analysis revealed that the tumors consisted of two distinct types of cells, reminiscent of syncytiotrophoblasts and cytotrophoblasts, as seen in the human choriocarcinoma. The tumors expressed HLA-G and cytokeratin (trophoblast markers) and hCG (a choriocarcinoma marker). Comparative analysis of gene expression profiles between iC³-1 cells and parental HTR8/SVneo cells revealed that iC³-1 cells expressed matrix metalloproteinases, epithelial-mesenchymal transition-related genes, and SOX3 at higher levels than parental trophoblastic cells. Administration of SOX3-specific short-hairpin RNA decreased SOX3 expression and attenuated the tumorigenic activity of iC³-1 cells, suggesting that SOX3 overexpression might be critically involved in the pathogenesis of choriocarcinoma. Our murine model represents a potent new tool for studying the pathogenesis and treatment of choriocarcinoma.
妊娠绒癌是一种恶性滋养细胞肿瘤。需要开发新的分子靶向治疗方法,以降低当前多药化疗的毒性,并成功治疗耐药病例。然而,绒癌肿瘤发生的分子机制尚不清楚,也尚未开发出合适的绒癌动物模型。在这项研究中,我们通过接种诱导绒癌细胞-1 (iC³-1) 细胞建立了绒癌模型,这些细胞源自 HTR8/SVneo 人滋养细胞,通过逆转录病毒转导激活的 H-RAS (HRASV12) 产生。iC³-1 细胞表现出丝裂原活化蛋白激酶 (MAPK) 和磷脂酰肌醇 3-激酶 (PI3K) 途径的持续激活,并在所有接种的小鼠中发展为致命肿瘤。组织病理学分析显示,肿瘤由两种不同类型的细胞组成,类似于合胞滋养层细胞和细胞滋养层细胞,类似于人绒癌。肿瘤表达 HLA-G 和细胞角蛋白(滋养层标志物)和 hCG(绒癌标志物)。iC³-1 细胞和亲本 HTR8/SVneo 细胞之间的基因表达谱比较分析表明,iC³-1 细胞比亲本滋养细胞表达更高水平的基质金属蛋白酶、上皮-间充质转化相关基因和 SOX3。SOX3 特异性短发夹 RNA 的给药降低了 SOX3 的表达并减弱了 iC³-1 细胞的致瘤活性,表明 SOX3 过表达可能在绒癌发病机制中起关键作用。我们的小鼠模型代表了研究绒癌发病机制和治疗的有力新工具。